Hofseth BioCare calls EGM to approve NOK 158m private placement

Hofseth BioCare ASA has convened an extraordinary general meeting for November 20, 2025, to approve a NOK 158 million private placement and related capital increase. The private placement involves the issuance of 87,811,110 new shares at NOK 1.80 per share, with 28,666,666 of these (T2 Shares) to be issued in Tranche 2 through debt conversion. The company also plans to divest shares in its U.S. subsidiary AecorBio Inc. for approximately USD 5 million.

Shareholders will vote on increasing the share capital by NOK 286,667 through the issuance of the 28,666,666 T2 Shares, subscribed by Hofseth International AS, waiving existing shareholders' preferential rights. The listing of Tranche 2 shares is contingent on an EEA listing prospectus, expected by Q1 2026.

Additionally, the board seeks authorization to issue up to 16,666,666 new shares for a subsequent offering (repair offering) to reduce dilution from the private placement, at a subscription price of NOK 1.80 per share. A general board authorization for capital increases, representing up to 20% of outstanding ordinary shares post-private placement, will also be proposed.